Inspire Medical Faces Investor Class Actions as Lead Plaintiff Deadline Nears

Plaintiffs allege inflated claims about Inspire V readiness led to a sharp post‑disclosure selloff in August 2025.

Overview

Investors have until January 5, 2026 to seek appointment as lead plaintiff in the federal securities case against Inspire Medical Systems.
A filed complaint in the U.S. District Court for the District of Minnesota, captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, asserts claims under Sections 10(b) and 20(a).
Filings allege the company misrepresented demand and launch preparation for the Inspire V device, citing incomplete training and onboarding at treatment centers, missing customer-approval IT processes, delayed claims‑software updates effective July 1, 2025, and unresolved Medicare reimbursement at launch.
On August 4, 2025 the company disclosed an elongated rollout and cut 2025 EPS guidance by more than 80%, and the stock fell about 32% the next day, dropping $42.04 to $87.91.
The putative class period runs from August 6, 2024 through August 4, 2025, with law firms including Bleichmar Fonti & Auld, Levi & Korsinsky, and Faruqi & Faruqi soliciting affected investors on a contingency basis.